Episodes of grade 3 and 4 toxicities on CCG-1891
. | DI . | DIVPI . | DDI . | |||
---|---|---|---|---|---|---|
No. episodes . | Episodes per 100 patient days4-150 . | No. episodes . | Episodes per 100 patient days4-150 . | No. episodes . | Episodes per 100 patient days4-150 . | |
Hepatic | ||||||
SGOT | 69 | 0.023 | 71 | 0.025 | 59 | 0.020 |
SGPT | 205 | 0.068 | 213 | 0.074 | 240 | 0.083 |
Alkaline phosphatase | 9 | 0.003 | 16 | 0.006 | 6 | 0.002 |
Bilirubin | 33 | 0.011 | 35 | 0.012 | 27 | 0.009 |
Pancreatic | 0 | 0.0 | 2 | 0.001 | 8 | 0.003 |
Renal | 3 | 0.001 | 0 | 0.0 | 4 | 0.001 |
Gastrointestinal | 11 | 0.004 | 10 | 0.004 | 24 | 0.008 |
Pulmonary | 6 | 0.002 | 9 | 0.003 | 10 | 0.003 |
Cardiac | 0 | 0.0 | 0 | 0.0 | 3 | 0.001 |
Nervous system | ||||||
Peripheral | 4 | 0.001 | 8 | 0.003 | 7 | 0.002 |
Central | 1 | 0.0 | 2 | 0.001 | 2 | 0.001 |
Dermatological | 8 | 0.003 | 12 | 0.004 | 12 | 0.004 |
Blood coagulation | 1 | 0.0 | 4 | 0.001 | 16 | 0.006 |
Infection | 21 | 0.007 | 20 | 0.007 | 46 | 0.016 |
. | DI . | DIVPI . | DDI . | |||
---|---|---|---|---|---|---|
No. episodes . | Episodes per 100 patient days4-150 . | No. episodes . | Episodes per 100 patient days4-150 . | No. episodes . | Episodes per 100 patient days4-150 . | |
Hepatic | ||||||
SGOT | 69 | 0.023 | 71 | 0.025 | 59 | 0.020 |
SGPT | 205 | 0.068 | 213 | 0.074 | 240 | 0.083 |
Alkaline phosphatase | 9 | 0.003 | 16 | 0.006 | 6 | 0.002 |
Bilirubin | 33 | 0.011 | 35 | 0.012 | 27 | 0.009 |
Pancreatic | 0 | 0.0 | 2 | 0.001 | 8 | 0.003 |
Renal | 3 | 0.001 | 0 | 0.0 | 4 | 0.001 |
Gastrointestinal | 11 | 0.004 | 10 | 0.004 | 24 | 0.008 |
Pulmonary | 6 | 0.002 | 9 | 0.003 | 10 | 0.003 |
Cardiac | 0 | 0.0 | 0 | 0.0 | 3 | 0.001 |
Nervous system | ||||||
Peripheral | 4 | 0.001 | 8 | 0.003 | 7 | 0.002 |
Central | 1 | 0.0 | 2 | 0.001 | 2 | 0.001 |
Dermatological | 8 | 0.003 | 12 | 0.004 | 12 | 0.004 |
Blood coagulation | 1 | 0.0 | 4 | 0.001 | 16 | 0.006 |
Infection | 21 | 0.007 | 20 | 0.007 | 46 | 0.016 |
Data shown are frequencies of grade 3 or 4 nonhematological toxicities, enumerated from the beginning of the second interim maintenance (DDI) or maintenance (DI and DIVPI).
SGOT indicates serum glutamic-oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase. See Table 1 footnote for other abbreviations.
Patient days were defined as the total number of days spent on therapy for all patients entering interim maintenance 2 (DDI) or maintenance (DI and DIVPI). Episodes per 100 patient days were calculated as number of episodes per total patient days divided by 100.